Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–70
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Females with a unilateral, non-inflammatory, non-multicentric, non-metastatic breast adenocarcinoma, not considered candidates for conservative management, and whose diagnosis had been histologically confirmed as T2-3, N0-1, M0 according to the tumor-nodes-metastasis (TNM) classification
Clinically or radiologically measurable lesion (in 2 dimensions)
Eastern Cooperative Oncology Group (ECOG) performance Status less than equal to (\<=) 1
You may not be if
Females presenting with brain metastases or a neurological or psychiatric disorder which could interfere with proper treatment compliance
Previous radiotherapy, chemotherapy, or hormonal therapy for breast cancer
Previous history of a malignancy in last 5 years other than cutaneous basal cell carcinoma or carcinoma in situ of the uterine cervix
Serious concomitant infection
Pregnant or lactating females
Clareo Health | To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer
